share_log
Moomoo 24/7 ·  Apr 24 16:02
FibroGen Announces Clinical Data From Dose Escalation Phase 1B Study of FG-3246 (for46) in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer Will Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment